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African-American (AA) women have earlier menarche on average than women of European ancestry (EA), and
earlier menarche is a risk factor for obesity and type 2 diabetes among other chronic diseases. Identification
ofcommongeneticvariantsassociated withageatmenarche hasapotentialvalue inpointingto thegeneticpath-
ways underlying chronic disease risk, yet comprehensive genome-wide studies of age at menarche are lacking
for AA women. In this study, we tested the genome-wide association of self-reported age at menarche with
common single-nucleotide polymorphisms (SNPs) in a total of 18 089 AA women in 15 studies using an additive
genetic linear regression model, adjusting for year of birth and population stratification, followed by inverse-
variance weighted meta-analysis (Stage 1). Top meta-analysis results were then tested in an independent
sample of 2850 women (Stage 2). First, while no SNP passed the pre-specified P < 5 3 1028 threshold for signifi-
cance in Stage 1, suggestive associations were found for variants near FLRT2 and PIK3R1, and conditional ana-
lysis identified two independent SNPs (rs339978 and rs980000) in or near RORA, strengthening the support for
this suggestive locus identified in EA women. Secondly, an investigation of SNPs in 42 previously identified me-
narche loci in EA women demonstrated that 25 (60%) of them contained variants significantly associated with
menarche in AA women. The findings provide the first evidence of cross-ethnic generalization of menarche
loci identified to date, and suggest a number of novel biological links to menarche timing in AA women.
INTRODUCTION
The timing of the age at first menses (menarche) is one of the
primary features shaping female reproductive history and is
associated with a number of current and later life health out-
comes (1). Earlier age at menarche is associated with increased
risk for breast cancer (2–4), reduced stature and increased risk of
obesity (5–7) and type 2 diabetes (8), whereas late menarche
may be associated with an increased risk of Alzheimer’s
disease (9) and stroke (10), as well as lower fertility (11,12).
Identification of genetic variants influencing variation in the
age at menarche may thus shed light on mechanisms involved
in a number of chronic diseases in women.
Age at menarche is under relatively strong genetic control, with
heritability estimated at 50% (13–16). Candidate gene associ-
ation studies point to the involvement of a number of genetic path-
ways, most notably those involved in steroid hormone signaling
and transport [e.g. estrogen receptor (ER) genes and sex
hormone binding globulin gene] and estrogen biosynthesis and
metabolism (such as CYP17, CYP19, CYP1A1, and CYP1B1)
(17), although many of these associations have not been reliably
replicated. In 2009, four large genome-wide association studies
(GWASs) in women of European ancestry (EA) were published
that together identified two novel genetic loci associated with
age at menarche, LIN28B and the intergenic region 9q13.2 (18–
21). Some of these variants are probably involved in general
growth rate, as LIN28B variants are associated with pubertal
timing, height and body mass index (BMI) growth in children
(20,22,23) as well as with body size and pubertal traits in animal
models (24). Variants near the 9q13.2 SNP are also associated
with height in GWAS (25). More recently, a GWAS in over
85 000 EA women identified a further 30 genome-wide significant
loci, and 10 suggestive loci, yielding a total of 42 loci associated
with menarche timing (26). A number of these had been previously
identified as obesity loci, highlighting genetic pleiotropy between
female adiposity and timing of menarche, an observation that
supports the long-recognized link between these traits from
epidemiologic studies (7,27).
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There is ethnic variation in the timing of menarche, with
African-American (AA) girls currently experiencing menar-
che 4–6 months earlier, on average, than EA girls in the
USA (6,28–32). In addition, compared with non-Hispanic
White women, non-Hispanic Black women in the USA tend
to have twice the prevalence of chronic diseases known to
be related to early age at menarche, including childhood
obesity (33), the Metabolic Syndrome (34) and diabetes
(35), as well as higher prevalence and earlier onset of hyper-
tension (36). Despite the significant heritability of age at me-
narche and the persistent ethnic variation in both age at
menarche and its associated diseases, only one recently pub-
lished study has sought to identify menarche-related genetic
variants in AA women (37).
Here, we present a meta-analysis of GWAS from 15 studies
including over 18 000 women to test the association of
common genetic variants with age at menarche in AA women.
We also conducted a targeted investigation of variants within a
+250 kb region around the 42 SNPs recently reported in EA
women, in order to test whether these loci contain variants asso-
ciated with menarche in AA women and to potentially identify
stronger markers of the associations. The study demonstrates
(i) suggestive evidence for association of age at menarche in
AA with a number of variants in loci involved in growth and
insulin signaling, (ii) multiple independent SNP associations
in or near RORA, previously identified as a possible menarche
locus in EA women and (iii) cross-ethnic generalization of the
majority of menarche loci identified to date in EA women.
RESULTS
A total of 18 089 AA women with self-reported age at menarche
were included in the Stage 1 meta-analysis. Participants were
drawn from seven population-based cohort studies and eight
breast-cancer case–control studies, in which association ana-
lyses were conducted in cases and controls separately. All
Stage 1 studies used agnostic, genome-wide SNP genotyping
arrays that were not enriched for SNPs in any particular molecu-
lar pathways or candidate regions (see Supplementary Material,
Table S1, and Methods). A total of 2850 AA women in the Black
Women’s Health Study (BWHS) were genotyped de novo as the
Stage 2 replication sample. Descriptive characteristics of each
study are presented in Table 1 and in Supplementary Material,
Text S1. Mean age at menarche in the studies was 12.6 years
(range 8–21 years). Not all studies reported the year of birth;
for those that did, the year of birth at the individual level
ranged from 1908 to 1978, and studies that were born later, on
average (e.g. CARDIA) had lower mean age at menarche than
studies that were born earlier (e.g. ARIC), which is consistent
with the downward secular trend in age at menarche during the
20th century (38).
An overview of the flow of experiments/analyses performed
in this study and a summary of their results is provided in
Figure 1. The following paragraphs provide details on the
results from these two primary experiments: (i) a meta-analysis
of GWAS of age at menarche in AA women and (ii) a targeted
interrogation of 42 loci previously reported to be associated
with age at menarche in EA women.
Meta-analysis of GWASs of age at menarche in AA women
All Stage 1 studies performed regression analyses to test the
linear association of each SNP genotype with age at menarche
using an additive genetic model. Covariates included study
center (if appropriate), year of birth (or age at study enrollment
if birth year not available) to account for known secular trends
and the first 10 principal components scores from EIGEN-
STRAT to adjust for population stratification. Further details
of the genotyping, quality control (QC) and analysis methods
used for each study are provided in Supplementary Material,
Table S1. A quantile-quantile plot of the meta-analysis
P-values shows that the test statistics follow the null expecta-
tions, with no excess of small P-values beyond that expected
by chance (Supplementary Material, Fig. S1; lambda ¼ 1.03).
No SNP passed the pre-specified P , 5 × 1028 threshold for
genome-wide significance in Stage 1 (Supplementary Material,
Fig. S2).
Table 2 displays SNPs with the lowest P-values from the Stage
1 meta-analysis, using the threshold of P , 1 × 1025, and other
criteria that are described in the Materials and Methods section.
Regional association plots for all 20 of these top regions are pro-
vided in Supplementary Material, Figure S3. There was little evi-
dence of heterogeneity of SNP effects by study as indicated by
P for heterogeneity generally .0.05 and never ,0.02. There
was no indication of systematic deviation of results in breast
cancer cases compared with controls or population-based
cohort samples (data not shown).
The most statistically significant association was with
SNP rs4557202, near B3GALNT3 (P ¼ 3.51 × 1027), a gene
involved in lipid synthesis and metabolic pathways. An intronic
enhancer SNP on chromosome 11q23 (rs11216435) near
DSCAML1 (Down-syndrome cell-adhesion molecule-like 1)
and an SNP on chromosome 15q22 (rs339978) near RORA
(the nuclear hormone receptor, RAR-like orphan receptor-
alpha) were associated at P , 1 × 1026. A second SNP (also
an intronic enhancer) near RORA (rs980000) was associated at
P ¼ 4.86 × 1026. These latter findings provide evidence of
cross-ethnic validation for RORA, which had suggestive (but
not confirmed) association with age at menarche in the EA
ReproGen analysis (26). The two intronic variants we identified
at RORA are common in AA women [minor allele frequency
(MAF) of 0.20 for rs339978 and 0.26 for rs980000] but not in
EA women (MAF of 0.02 and 0.05 in 1KGP EUR). These
SNPs are in low linkage disequilibrium (LD) with one another
in HapMap 1000 Genomes Project (1KGP) African samples
(AFR in 1KGP, r2 ¼ 0) and are only modestly correlated in
EA populations (CEU in 1KGP, r2 ¼ 0.34). Neither of these
SNPs were in LD in either population with the index signal
(rs3743266) reported previously at RORA in women of EA
(r2 ¼ 0).
We also replicated the ZNF483 locus previously reported in
EA women (26) in AA women. The two most significant associa-
tions in Stage 1 were intronic enhancer variants rs7873730
and rs10441737 near ZNF483 on chromosome 9q31. SNP
rs10441737 is a near-perfect proxy for the known menarche
variant rs10980926 at this locus in EA women (EUR in 1KGP,
r2 ¼ 0.98), with LD also observed in African samples (AFR in
1KGP, r2 ¼ 0.44). The SNP rs7873730 was imputed in all
studies (MACH r2 was between 0.72 and 0.86 across studies),
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was less common in each population than the index SNP (MAF
of 0.06 in EUR and 0.10 in AFR) and was only weakly correlated
with either of the two SNPs in both EUR and AFR (r2 of 0.08–
0.18).
Conditional analysis
To further explore the evidence of multiple independent signals
within the RORA and ZNF483 loci, we performed conditional
analyses in which both of our top SNPs and the index SNP
reported for EA were included as covariates in each of the two
independent regression models (Table 3; Fig. 2). For the
RORA locus, we found evidence of two independent signals;
both rs980000 (P ¼ 6.8 × 1025) and rs339978 (P ¼ 2.5 ×
1023) remained significant when considered in the same
model with the EA index SNP. This finding suggests that there
may be multiple functional variants for menarche at this locus
in AA women. For ZNF483, we found evidence of a single
signal, as only one of the three SNPs (rs10441737) remained
nominally significant (P ¼ 0.025) when rs7873730 and
rs10980926 (the EA index SNP) were included in the regression
model.
Stage 2 analysis in the black women’s health study
We examined the 20 top SNPs from the Stage 1 meta-analysis in
AA women from the BWHS. For 16 of the 20 SNPs that under-
went testing in Stage 2, the direction of effect in the replication
sample was consistent with Stage 1 (Table 2). Two SNPs also
replicated at a nominal P value (,0.05): rs8014131 near
FLRT2 (BWHS P ¼ 0.021; combined P ¼ 3.4 × 1027) and
rs10940138 near PIK3R1 (BWHS P ¼ 0.018; combined
P ¼ 4.1 × 1027), which is involved in the metabolic functions
of insulin. Suggestive evidence for replication (consistent
direction and nominally significant P value) was also noted
for rs12907866 near the aromatase gene CYP19A1 (BWHS
P ¼ 0.065; combined P ¼ 4.4 × 1027) centrally involved in
estrogen synthesis, and rs17669535 in DLGAP2 (BWHS
P ¼ 0.057; combined P ¼ 6.4 × 1027). No SNPs passed a
Bonferroni-corrected P-value threshold for significance in
Stage 2.
Examination of the Stage 1 findings in EA women
We also evaluated potential associations between the 20 top
SNPs from our Stage 1 meta-analysis in AA women and age at
menarche in women of EA using data from the ReproGen con-
Table 1. Description of participating cohorts
Consortium name/cohort name Cohort acronym Age at menarche Birth year






CARE (cases) 357 12.4 (1.7) 8–18 NA NA
CARE (controls) 215 12.3 (1.74) 9–18 NA NA
The Carolina Breast Cancer Study CBCS (cases) 634 12.6 (1.8) 8–21 NA NA
CBCS (controls) 586 12.6 (1.75) 8–18 NA NA
The Multiethnic Cohort MEC (cases) 532 12.9 (1.66) 10–17 NA NA
MEC (controls) 972 13.2 (1.6) 10–17 NA NA
The Nashville Breast Health Study NBHS (cases) 304 12.6 (1.99) 8–21 NA NA
NBHS (controls) 182 12.4 (1.9) 8–21 NA NA





575 12.6 (1.8) 8–20 NA NA
NC-BCFR/SFBCS
(controls)
269 12.6 (1.8) 8–20 NA NA
The Prostate, Lung, Colorectal, and
Ovarian Cancer Screening Trial
PLCO (Cases) 56 13.3 (1.3) 9–16 NA NA
PLCO (controls) 116 13.1 (1.76) 9–16 NA NA
The Women’s Circle of Health Study WCHS (cases) 260 12.7 (1.9) 9–19 NA NA
WCHS (controls) 238 12.7 (1.7) 9–18 NA NA
The Wake Forest University Breast
Cancer Study
WFBC (cases) 112 12.5 (1.6) 8–16 NA NA





ARIC 1,690 12.87 (1.66) 9–17 1934 1921–1945
Coronary Artery Disease
in Young Adults
CARDIA 630 12.48 (1.47) 9–17 1959 1957–1969
Cleveland Family Study CFS 169 12.22 (1.37) 10–16 1964 1908–1997
Jackson Heart Study JHS 1,228 12.77 (1.70) 9–17 1952 1910–1982
Women’s Health Initiative WHI 8,086 12.6 (1.64) 9–17 1935 1913–1948
Healthy Aging in Neighborhoods
of Diversity across
the Life Span
HANDLS 617 12.6 (1.80) 9–17 1962 1946–1980
Bogalusa Heart Study BHS 145 12.5 (1.37) 9–17 1966 1959–1978
TOTAL Stage 1 18,089
Black Women’s Health Study
(Stage 2 Replication Cohort)
BWHS 2,850 12.4 (1.6) 9–17 1947 1925–1974
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sortium (Supplementary Material, Table S2). AA associations
were directionally consistent with EA associations for 14 of
the 20 variants, 3 of which were associated with age at menarche
(Bonferoni-corrected P , 0.05). We found suggestive evidence
of association near AKT3. The SNP rs320320 was associated in
ReproGen at P ¼ 1.06 × 1023, and the combined Stage 1 AA +
ReproGen EA meta-analysis yielded P ¼ 1.18 × 1027). AKT3
is one of the AKT kinases, which encodes RAC-gamma
serine/threonine-protein kinase, and regulates cell signaling in
response to insulin and growth factors. In addition to AKT3,
Figure 1. Overviewof analysis and results. Flow of analyses and brief summary of results from each analysis are presented for the genome-wide meta-analysis of age at
menarche in AA women and for the targeted interrogation of 42 menarche loci previously reported in EA women.
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Table 2. Meta-analysis of age at menarche in AA women: Stage 1 and 2 resultsa
SNP Chr. Nearest gene Position (Build 36) Allelesb EAFc Stage 1 (maximum n ¼ 18 089) Stage 2 (maximum
n ¼ 2850)
Stage 1 and Stage 2
(maximum n ¼ 20 939)
Effect b (SE)d P Phet Effect b (SE) P Effect b (SE) P
rs4557202e 3 B3GALNT1 162303218 C/G 0.43 24.90 (0.96) 3.51E 2 07 0.238 20.50 (2.24) 0.822 24.21 (0.88) 1.86E 2 06
rs11216435 11 DSCAML1 116894142 T/C 0.32 5.11 (1.02) 6.33E 2 07 0.966 0.30 (2.49) 0.904 4.41 (0.95) 3.31E 2 06
rs339978 15 RORA 58724694 T/C 0.20 5.90 (1.21) 9.95E 2 07 0.193 2.00 (2.85) 0.484 5.31 (1.11) 1.76E 2 06
rs1476150 2 NAP5 133592865 C/G 0.65 5.69 (1.18) 1.23E 2 06 0.683 21.36 (2.35) 0.056 4.28 (1.05) 4.51E 2 05
rs7754121 6 HDGFL1 23281592 A/G 0.10 7.69 (1.59) 1.36E 2 06 0.434 20.28 (3.79) 0.942 6.49 (1.47) 9.61E 2 06
rs320320 1 AKT3 241901809 A/G 0.48 4.55 (0.95) 1.84E 2 06 0.117 1.03 (2.29) 0.652 4.03 (0.88) 4.68E 2 06
rs12907866 15 CYP19A1 49332746 A/G 0.84 6.15 (1.31) 2.53E 2 06 0.587 5.63 (3.05) 0.065 6.06 (1.20) 4.36E 2 07
rs6468994 8 ZFPM2 106365896 T/C 0.64 4.67 (1.00) 2.81E 2 06 0.309 22.69 (2.34) 0.251 3.54 (0.92) 1.14E 2 04
rs11071033 15 UNC13C 52167492 T/C 0.71 4.80 (1.03) 3.54E 2 06 0.749 2.67 (2.50) 0.286 4.49 (0.96) 2.70E 2 06
rs7807441 7 FLJ13195 66826223 T/C 0.55 24.32 (0.94) 4.14E 2 06 0.618 22.28 (2.25) 0.311 24.02 (0.87) 3.48E 2 06
rs17669535 8 DLGAP2 1231631 C/G 0.97 14.50 (3.15) 4.20E 2 06 0.966 14.49 (7.61) 0.057 14.50 (2.91) 6.37E 2 07
rs6947406 7 C7orf10 41013150 A/G 0.87 26.43 (1.40) 4.78E 2 06 0.963 20.16 (3.31) 0.961 25.48 (1.29) 2.34E 2 05
rs980000 15 RORA 58688255 T/C 0.26 4.88 (1.07) 4.86E 2 06 0.048 3.55 (2.57) 0.168 4.69 (0.99) 2.03E 2 06
rs8014131 14 FLRT2 85033609 A/C 0.42 24.48 (0.98) 5.24E 2 06 0.157 25.29 (2.29) 0.021 24.61 (0.90) 3.44E 2 07
rs7819115 8 DLGAP2 1549163 A/C 0.36 24.52 (0.99) 5.52E 2 06 0.471 21.19 (2.36) 0.614 24.01 (0.92) 1.18E 2 05
rs7873730 9 ZNF483 113343500 A/T 0.88 27.43 (1.65) 6.35E 2 06 0.026 24.84 (2.92) 0.104 26.82 (1.44) 2.17E 2 06
rs10441737 9 ZNF483 113341406 T/C 0.58 24.37 (0.97) 6.55E 2 06 0.084 20.11 (2.24) 0.961 23.70 (0.89) 3.22E 2 05
rs10940138 5 PIK3R1 67230225 T/C 0.19 5.43 (1.21) 6.78E 2 06 0.526 6.77 (2.87) 0.018 5.64 (1.11) 4.09E 2 07
rs7911165 10 EBF3 131516640 T/C 0.54 4.72 (1.05) 7.09E 2 06 0.985 1.80 (2.21) 0.415 4.18 (0.95) 1.05E 2 05
rs2796200 1 ZRANB2 71431476 A/G 0.66 4.46 (0.99) 7.10E 2 06 0.745 22.81 (2.35) 0.232 3.35 (0.92) 2.45E 2 04
aTop independent (pairwise r2 , 0.3) SNPs, all with n . 10 000 out of 18 089, MAF . 0.03, and P , 1025 in meta-analysis.
bEffect/non-effect allele.
cEffect allele frequency.
dEffect b is in weeks.


































both of the SNPs near ZNF483 (rs7873730 and rs10441737) also
replicated in EA women, which was expected given that ZNF483
was originally identified as a menarche locus in the ReproGen
cohorts (described above) and because these SNPs were in
high LD with the index SNP in this locus.
Interrogation of previously published menarche-associated
Loci
The second goal of our study was to systematically interrogate
the set of 42 menarche loci discovered in EA populations in
AA women to confirm cross-ethnic replication of these loci
and to identify possible stronger markers of the signals. First
we examined the 42 EA index SNPs in these loci and found 26
had the same direction of effect on age at menarche in AA
women, although only four of these were also nominally asso-
ciated with age at menarche in our AA samples (P , 0.05).
Other than ZNF483 (discussed above), these included SNPs
near CCDC85A, C6orf173, and RXRG (Supplementary Mater-
ial, Table S3). None of these passed the Bonferroni-adjusted
P-value threshold for significance (P , 0.0011).
We next investigated SNPs in a 250 kb region surrounding the
42 index SNPs that were associated with age at menarche in EA
(see Materials and Methods) (Table 4), using a Bonferroni cor-
rection for the number of effective SNPs queried in each
region. Generally, the SNP with the lowest P-value in African
populations was in low LD with the index EA SNP in AA
women (r2 , 0.2) but was often in high LD with the index
SNP in European populations (r2 . 0.8), reflecting the same
signal but better localizing it than was possible in the EA
studies. Supplementary Material, Figure S4 shows regional asso-
ciation plots of age at menarche in AA women with SNPs within
each 42 of the interrogated loci. The main finding from this ana-
lysis was that we found cross-population validation for a large
proportion of the 42 loci (25 of 42, or 60%). The strongest evi-
dence of association was found for SNPs in RORA and
ZNF483 (as discussed above in relation to the top Stage 1
results), but there was also some evidence for cross-population
locus replication of seven obesity-associated loci (26,39), in-
cluding FTO (rs12149832, P ¼ 1.6 × 1023), SEC16B
(rs543874; P ¼ 1.47 × 1022), STK33/TRIM66 (rs12575252;
P ¼ 3.27 × 1022) and RXRG (rs3767342; P ¼ 4.49 × 1022)
where SNPs were in high LD with the index SNP in EUR
(r2 . 0.8), as well as BSX (P ¼ 4.39 × 1023), TMEM18
(rs2685252; P ¼ 2.06 × 1022) and LRP1B (rs7607295;
P ¼ 4.74 × 1022), which were not in high LD with the index
SNP in EUR (r2 , 0.1). In addition, as in EA women, age at me-
narche was associated with genetic variants near LIN28B,
PLCL1, NR4A2, MKL2 (corrected P value ,5 × 1023 for all),
and with variants in INHBA (P ¼ 1.3 × 1022). Inhibin A is
secreted by the granulosa cells of the ovarian follicles in the
ovaries to provide negative feedback on follicle-stimulating
hormone and is a strong candidate gene for pubertal timing.
Next, we sought to identify stronger markers of the index
signals in AAs through additional fine-mapping (see details of
the approach in Materials and Methods). We found SNPs in 8
of the 42 EA regions that were more strongly associated with
age at menarche in AA women when compared with the index
signal in EA women (i.e. had a P-value for association with me-
narche ,0.004, and a P value at least 1 degree of magnitude
lower than the P for the corresponding index association in EA
women), and also were in moderate to strong LD with the EA
index SNP with r2 . 0.4 with the index SNP in EA (i.e. repre-
sented the same genetic ‘signal’) (Table 5). These included
SEC16B, CCDC85A, EEFSEC, LIN28B, BSX, NARS2, STK33,
and FTO. For instance, at the obesity-related locus SEC16B,
we detected a variant (rs543874) approximately 50 kb upstream
of the index signal previously identified in EAs (rs633715) that
was more strongly associated with menarche in AA women
(P ¼ 4.9 × 1024) than was the index signal (P ¼ 0.12). SNP
rs543874 is more strongly correlated with rs633715 in EA
populations (r2 ¼ 0.91 in 1KGP EUR) than in AA populations
(r2 ¼ 0.18 in 1KGP AFR), which suggests rs543874 may be a
better marker of the putatively functional variant in AAs.
These relationships are illustrated for the index SNP and the
stronger marker in SEC16B in a regional association plot
(Fig. 3). Similarly, in the widely replicated obesity locus FTO,
rs12149832 may be a stronger marker of the functional variant
due to its stronger evidence of association in AA women
(P ¼ 2.0 × 1024) when compared with the index SNP identified
in EA women (rs9939609, P ¼ 0.83), and because it again repre-
sents the same signal as the index SNP in EUR populations
(r2 ¼ 0.88 in 1KGP EUR) but not in AFR populations
(r2 ¼ 0.05 in 1KGP AFR). Of interest, five of the eight stronger
marker SNPs in this analysis were found in/near loci previously
implicated in adiposity via GWA (SEC16B, FTO) (39) were
Table 3. Conditional analysis of multiple SNPs near ZNF483 and RORA
Chr., gene SNP Position (Build 36) Coded allele,
frequency in AFR
Marginal betaa, P Conditional betaa, P
9, ZNF483 rs10980926 (index) 113333455 A, 0.61 2.34, 0.019 20.12, 0.93
9, ZNF483 rs7873730 113343500 A, 0.88 27.43, 6.4 × 1026 20.56, 0.77
9, ZNF483 rs10441737 113341406 T, 0.58 24.37, 6.6 × 1026 23.22, 0.025
15, RORA rs3743266 (index) 58568805 C, 0.33 20.69, 0.49 20.016, 0.43
15, RORA rs339978 58724694 T, 0.20 5.90, 1.0 × 1026 3.68, 2.54 × 1023
15, RORA rs980000 58688255 T, 0.26 4.88, 4.9 × 1026 4.31, 6.78 × 1025
aBeta values are for effect of SNP on menarche age, in weeks. Conditional analyses were conducted in the largest cohort/studies (WHI, CARe and AABC) using
individual-level genotype data in two linear regression models (one for each locus), each of which included the three SNPs, birth year (or enrollment age), study center
(if applicable) and the top 10 PCs as covariates. The results were then meta-analyzed using METAL. Bonferroni-corrected P values were used to identify independent
signals in the conditional analyses, with P , 0.05 as the criterion for independence.
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associated with BMI in the GIANT consortium (STK33/
TRIM66, NARS2/GAB2) (26), or are involved in neuronal
feeding-control circuits (BSX) (40).
eQTL analysis of lead AA SNPs
For the 42 EA loci, there were 29 SNPs with at least one UCSC,
Vega or RefSeq transcript showing expression in Yoruban
African lymphoblastoid cell lines (LCLs). A total of 109 cis-
regulatory SNPs were compared for the analysis of the index
SNPs, while a total of 111 cis-regulatory SNPs were compared
for the AA top SNP analysis. While 11.4% of the queried
index SNPs positively overlapped with cis-regulatory SNPs
observed in YRI LCLs, twice as many (23.4%) of the top AA
SNPs from the regional analysis had positive overlap with cis-
regulatory SNPs [nominal P value for x2 ¼ 0.026; P (Permuta-
tion) ,0.05]. This provides some evidence for the greater func-
tional relevance of the SNPs identified in AA women when
compared with the EA index SNPs. When limiting the compari-
son to SNPs that were significantly stronger markers of the index
signal in the fine-mapping experiment, their overlap with cis-
regulatory SNPs was not found to be significantly greater than
for the index SNPs.
DISCUSSION
Identification of genetic variation controlling the development
of chronic disease risk factors in childhood, such as early menar-
che, is important because it may point to effective targets for en-
vironmental and behavioral interventions in early life, before
disease processes are fully entrenched. AA women now experi-
ence significantly earlier sexual development (28) and carry a
much higher burden of obesity and diabetes than EA women
(33,35); therefore, the search for genetic determinants of menar-
che timing may be of particular value in this population. None-
theless, virtually all GWAS to date have been conducted in
individuals of EA (41), and this is true of menarche GWAS as
well; a recent systematic review on the genetics of menarche
(42) found only one existing study that provided any estimates
of measured genotype effects on age at menarche for AA
women. Subsequently, there has been one study published
using a targeted genome-wide approach [i.e. using the Metabo-
chip (43) in 4000 AA women (37)]. In that study, no SNP as-
sociation passed correction for multiple testing, and relatively
poor coverage by the Metabochip of the previously reported me-
narche loci in EA women meant that cross-ethnic replication and
generalization study was hampered (37).
Figure 2. Conditional analysis identifies two independent signals for age at menarche near RORA, both of which are different from the previously identified index SNP
in EA women.SNPsare plottedusing Locus Zoom by positionon the chromosome against associationwith age at menarche (2log10 P). Estimated recombination rates
are plotted in blue to reflect local LD structure using the 1KGP AFR reference panel, and the SNPs surrounding the top SNP from the Stage 1 meta-analysis (rs339978,
purple diamond) are color coded to reflect their LD with this SNP. Both the first (represented by rs339978, P ¼ 1 × 1026) and the second signal (represented by
rs980000, P ¼ 2 × 1026) were independent of the index SNP (rs3743266) previously reported for EA women (see Table 3).
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Meta-analysis of GWASs of age at menarche
The present study remains the largest and most comprehensive
genetic examination of menarche timing in AA women to
date, including all known available data (from 15 observational
cohort and case–control studies) in AA women having both age
at menarche information and genome-wide genotype data.
Nonetheless, it included far fewer samples than are now avail-
able for EA women (≥100 000 in ReproGen). Effect sizes of
the variants found via GWA in EA women (26) were fairly
small (e.g. accounting for between 1 and 6 weeks variation in
age at menarche per copy of the risk allele); therefore, our lack
of genome-wide significant associations could stem from a
lack of statistical power. Our power calculations show
(Supplementary Material, Fig. S5) that for SNPs with MAF .
0.2, we had ≥80% power to detect a relatively small effect
size [e.g. 6.5 weeks (0.12 years) earlier age at menarche per
copy of the risk allele]. This is an effect size at the upper end
of the range observed previously in EA populations [e.g. in
LIN28B, a 6.9-week reduction in age at menarche per allele
copy has been seen (18,20,21,26)]. As many of the SNPs identi-
fied in EAs were novel, it is also possible that the reported effect
sizes in EA women were overestimated (i.e. the phenomenon of
the ‘winner’s curse’), which would indicate that while our study
was adequately powered to test variants having effects in the
range of previously reported SNPs, it was in reality substantially
underpowered.
Table 4. Twenty-five of 42 menarche loci identified in European Americans generalize to AA womena
Nearest genes Chr Index SNP
identified in EA
womenb
















RXRG 1 rs466639 rs3767342 0.839 0.877 T (0.85) 4.26 0.045
SEC16B 1 rs633715 rs543874 0.144 0.917 A (0.75) 3.77 0.015
LRP1B 2 rs12472911 rs7607295 0.206 NA T (0.90) 28.83 0.047
PLCL1 2 rs12617311 rs7557664 0.037 0.11 A (0.48) 23.62 0.003
NR4A2 2 rs17188434 rs1113060 NA 0.002 T (0.36) 24.25 0.0004
CCDC85A 2 rs17268785 rs17047854 0.318 0.943 A (0.34) 3.41 0.010
TMEM18 2 rs2947411 rs2685252 0.004 0.031 T (0.75) 3.41 0.021
SFRS10 3 rs2002675 rs4686718 0.002 0.073 T (0.35) 23.23 0.05
EEFSEC 3 rs2687729 rs9819578 0.543 0.075 T (0.23) 5.47 0.024
ECE2 3 rs3914188 rs6770142 0.044 0 A (0.30) 2.87 0.093
3q13.32 3 rs6438424 rs16827902 0.012 NA T (0.94) 12.58 0.036
TMEM108 3 rs6439371 rs7613434 0.129 0.005 A (0.13) 24.65 0.029
RBM6;RBM5 3 rs6762477 rs12629572 0.003 0.071 T (0.76) 3.68 0.075
CCDC71 3 rs7617480 rs1464567 0.113 0.243 C (0.81) 22.22 0.49
VGLL3 3 rs7642134 rs2879790 0.017 0.046 A (0.21) 28.18 0.012
PHF15 5 rs13187289 rs12655967 0.023 0.017 A (0.53) 27.71 0.029
JMJD1B 5 rs757647 rs11750854 0.013 0.082 A (0.67) 24.27 0.46
C6orf173 6 rs1361108 rs9401888 0.404 0.806 A (0.78) 3.62 0.018
PRDM13 6 rs4840086 rs7740247 0.000 0.009 C (0.02) 215.27 0.085
LIN28B 6 rs7759938 rs9386427 0.229 0.075 T (0.29) 4.10 0.0025
INHBA 7 rs1079866 rs17171859 0.097 NA C (0.95) 11.89 0.010
PXMP3 8 rs7821178 rs6473010 0.042 0.006 A (0.99) 247.64 0.097
ZNF483 9 rs10980926 rs7873730 0.093 0.118 A (0.88) 27.43 0.0021
TMEM38B 9 rs2090409 rs7041138 0.002 0.129 T (0.51) 3.31 0.015
NARS2 11 rs10899489 rs1006441 0.105 0.841 C (0.15) 3.90 0.10
PHF21A 11 rs16938437 rs11600515 0.014 0.007 C (0.04) 8.61 0.01
STK33 11 rs4929923 rs12575252 0.439 0.959 C (0.51) 3.10 0.033
BSX 11 rs6589964 rs17126930 0.128) 0 T (0.91) 26.42 0.0044
ARNTL 11 rs900145 rs7925241 0.025 NA A (0.87) 26.22 0.094
C13orf16 13 rs9555810 rs1163630 0.024 0.028 C (0.66) 23.11 0.16
BEGAIN 14 rs6575793 rs941930 0.003 0.015 A (0.16) 4.73 0.011
RORA 15 rs3743266 rs339978 0.012 0.008 T (0.20) 5.90 0.00004
IQCH 15 rs7359257 rs7174933 0.00 NA A (0.02) 212.76 0.11
NFAT5 16 rs1364063 rs8054051 0.015 NA A (0.97) 214.49 0.74
MKL2 16 rs1659127 rs39826 0.035 0.019 A (0.26) 23.84 0.0082
FTO 16 rs9939609 rs12149832 0.057 0.934 A (0.12) 25.54 0.0016
CA10 17 rs9635759 rs12452390 0.001 0.001 T (0.86) 4.98 0.011
FUSSEL18 18 rs1398217 rs1036349 0.026 0.133 T (0.08) 24.22 0.32
SLC14A2 18 rs2243803 rs9973059 0.004 0.001 C (0.84) 3.88 0.092
CRTC1 19 rs10423674 rs875396 0.003 0.067 A (0.27) 22.55 0.54
PIN1 19 rs1862471 rs10425175 0.032 0 T (0.27) 3.30 0.079
PCSK2 20 rs852069 rs4814606 0.006 0.011 A (0.13) 4.44 0.034
aLocus generalization defined as Bonferonni-corrected P value for best SNP in the region ,0.05.
bIndex SNPs in EA women are from Elks et al. (26).
cAllSNPs in a 250 kb region in either directionof the indexSNP were interrogated for association with age at menarche and the SNP with the lowestBonferonni-correct
P value was considered the best.
dBonferonni-corrected P value (0.05/n), based upon number of n independent tests (SNPs) within each region; corrected P values , 0.05 are shown in bold.
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The primary outcome of our GWA experiment was to provide
the first cross-ethnic validation of RORA, strengthening the evi-
dence for its role in menarche. Genetic variants near RORA were
previously reported to influence age at menarche in EA women,
but at P-values below genome-wide significant thresholds (26).
RORA encodes one of the ROR nuclear receptors that regulate
the transcription of numerous other genes and is expressed in
human endometrium (44). Recently, RORA expression has
been found to regulate aromatase (CYP19A1), which converts
testosterone to estrogen (45). A SNP in CYP19A1 was among
our top Stage 1 results and was marginally associated in Stage
2 (P ¼ 0.065). Variants in genes in the CYP19 gene family
have been found to be associated with age at menarche (46,47)
as well as other reproductive traits in women (17,18,48,49). Fur-
thermore, a conditional analysis identified two independent
signals in RORA in AA women, both of which were independent
of the previously reported index SNP identified in EA women.
Localization of multiple independent variants that are statistical-
ly associated with disease traits is an important first step toward
identifying causal variants. Our results suggest two independent
signals in/near RORA, refining this putative menarche locus.
In addition, results of the GWA meta-analysis highlight bio-
logical pathways that may be important in AA women. A
number of the most strongly associated variants from this
meta-analysis implicate growth factor and insulin signaling in
menarche timing. SNPs in Stage 1 that were also associated
with menarche age in Stage 2 included rs10940138 near
PIK3R1 (phosphatidylinositol 3-kinase receptor 1, alias p13k
in mice), which is part of the PI3K/AKT/mTOR inflammatory
pathway. Enhanced activity of this pathway is strongly impli-
cated in ER-positive breast cancer, ovarian cancer and endomet-
rial cancer (50), is involved in over 30 insulin-signaling
networks (51) and contains variants associated with body
fatness and leptin levels (52). The second SNP from Stage 1
that was associated with menarche in the Stage 2 sample
(rs8014131) is located near FLRT2, encoding the fibronectin
leucine-rich transmembrane protein 2. FLRT2 acts as a
cell-adhesion or signaling molecule and interacts with numerous
growth factors including FGFR1, GnRH and GnRHR to control
diverse developmental processes. Lastly, a suggestive associ-
ation was noted with SNP rs320320 near AKT3 in Stage 1 and
was also associated with menarche in our sample of EA
women in the ReproGen study (P ¼ 1 × 1023, combined
P-value ¼ 1 × 1027). AKT3 (also known as protein kinase B)
is a member of the serine/threonine-protein kinase family, and
functions to regulate extracellular signals including platelet-
derived growth factor, insulin and insulin-like growth factor 1
(53,54).
Interrogation of menarche loci reported in EA women
While there are numerous pitfalls in the use of diverse popula-
tions for GWA at present, including poorer genomic coverage
with existing SNP panels and lower imputation quality (55)
and complex admixture patterns across regions of the genome
(56), diverse populations are very important in building on the
findings in individuals of EA (41,55,57). Owing to wide popula-
tion variation in allele frequencies, sampling of diverse popula-
tions is critical, and African ancestry populations in particular
should theoretically yield greater resolution on the location of
causal variants influencing a trait, given their lower average
LD (56). We undertook two investigations to leverage these
properties of AA populations to expand the information on me-
narche variants already identified in EA women. First, we
hypothesized that we would find locus replication (association
of SNPs in the same region), but not necessarily SNP replication
in AA women. Therefore, we examined SNPs in a 250 kb region
of the previously reported menarche loci in EAs. Secondly, we
hypothesized that by taking advantage of the lower LD structure
in AAs, we could gain insight into the fine structure of these loci
and localize potentially causal variants.
As recently shown for lipid traits, significant inter-population
differences exist in the contributions of individual SNPs within a
given locus as well as their magnitude of effect on a given trait
(57,58). Similarly, in the present analysis, none of the 42 index
SNPs identified in EA women was associated with age at menar-
che in AA women after Bonferroni correction for multiple
testing. In contrast, 60% of the 42 loci contained SNPs (within
+250 kb of the index SNP) were associated with menarche
after region-based Bonferroni correction, showing significant
overlap in the genes involved in menarcheal timing across
race/ethnicity. This finding is important, first, because it
strengthens the evidence for these particular loci being involved
in menarcheal timing generally. We found, further, that the SNP
with the lowest P-value in AA women in each region generally
represented the same signal as in EA women (was in high LD




















1, SEC16B rs633715 C, 0.10 22.5, 0.12 rs543874 A/G, 0.75 3.8, 4.9 × 1024 0.91 0.18
2, CCDC85A rs17268785 A, 0.74 23.1, 0.017 rs17047854 A/G, 0.34 3.4, 5.8 × 1024 0.99 0.52
3, EEFSEC rs2687729 A, 0.66 21.8, 0.075 rs2075402 T/C, 0.27 23.2, 2.2 × 1023 0.56 0.14
6, LIN28B rs7759938 C, 0.53 2.5, 0.15 rs314266 T/C, 0.33 23.8, 2.9 × 1024 0.65 0.53
11, BSX rs6589964 A, 0.38 0.3, 0.72 rs1461499 A/C, 0.63 3.5, 3.8 × 1024 0.41 0.06
11, NARS2 rs10899489 A, 0.31 0.7, 0.48 rs1006441 C/G, 0.15 3.9, 3.8 × 1023 na na
11, STK33 rs4929923 C, 0.55 21.5, 0.11 rs12575252 C/G, 0.51 3.1, 9.9 × 1024 0.92 0.55
16, FTO rs9939609 A, 0.47 20.2, 0.83 rs12149832 A/G, 0.12 25.5, 2.0 × 1024 0.88 0.05
aSNPs selected were those within +250 kb of index signal, with r2 . 0.4 with index SNP in EUR, P value for marker association ,0.004 and at least 1 degree of
magnitude lower than p for index SNP.
bLD (r2) between Index SNP and Stronger Marker SNP is based on 1000 Genome Project.
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with the index SNP in EA populations), although it was in low
LD with the index EA SNP in AA populations. These findings
point to the value of examining African Ancestry populations
to better localize associations identified in EA populations. We
also showed modest evidence in our eQTL analysis that particu-
lar SNPs in the 42 loci that were associated with menarche in AA
women were more likely to influence local gene expression than
were the index SNPs in EA women. A limitation of eQTL ana-
lysis is that expression is tissue and cell-type specific, and the
cell-type (LCL) used here, while from Yoruban (African) ances-
try samples, may not be as informative for investigation of gene
variants regulating reproductive timing as hypothalamic or
ovarian tissues would be, if available.
In a second analysis to identify specific SNPs in the 42 loci that
may better capture the association of the EA signal in AAs, we
targeted only SNPs in LD (r2 . 0.4) with the index signal in
EAs. Through this fine-mapping work, we identified SNPs in
at least eight regions that better captured the association with
age at menarche in AAs than the SNPs identified in EAs, most
of which were in obesity-related loci such as FTO and
SEC16B. In the case of SEC16B, the LD structure of AA
women was particularly helpful in localizing the signal to a
smaller region. The results suggest a close link between female
adiposity and the timing of pubertal development in AA
women as was found for EA women (26) and again showcase
the value of examining AA populations to narrow the subset of
potentially functional alleles in loci identified via GWA in EA
populations. In future, this work may be enhanced through trans-
ethnic meta-analysis (59), which takes into account the expected
similarity in allelic effects in more closely related populations
while allowing for heterogeneity between more diverse ethnic
groups. This approach has already been shown to both increase
power to detect association and improve localization of causal
variants by combining diverse population data in a single
meta-analysis (60,61).
Interpretation
The lack of strong genome-wide significant associations, in
combination with significant overlap in loci associated with
age at menarche in both AA and EA women, should not be inter-
preted to mean that ethnic differences in menarche timing are
driven solely by environmental factors. First, African ancestry
populations have greater haplotype diversity than European
and Asian populations, which yields lower sensitivity for
GWA because lower genome-wide LD makes the identification
of loci less sensitive given the same degree of genomic coverage
on a given genotyping array. Better imputation strategies are
needed using population-specific sequencing data to detect low-
frequency variants and provide better coverage of genomic
regions for African ancestry populations (62,63). However,
greater haplotypic diversity also allows greater refinement of
loci of interest (64), and may have contributed to our greater
success in refining multiple RORA signals than in the European
cohort studies of menarche (26). Secondly, there are other
classes of genetic variants (e.g. less common alleles, copy
number variants, other structural variants) that were not
assayed here that may be shown to play a role in age at menarche.
Thirdly, gene-by-environment interactions may have masked
the effect of genetic variants; the presence of such interactions
on a genome-wide basis requires much larger sample size than
is available at this time for AA women. Therefore, expansion
to additional cohorts to increase the sample size to reach the
sizes now available for EA individuals (.100 000) will also
be necessary before a full assessment of genetic and environ-
mental contributors to ethnic variation in menarche timing can
be made.
Limitations
In addition to the issue of sample size and the focus on common
variants discussed above, there are a number of limitations of the
study. The participating studies used SNP arrays that were
designed to capture common variants in populations of EA and
thus, a substantial fraction of common variation in AA popula-
tions is likely to have been missed or imprecisely tagged follow-
ing imputation to a reference source such as HapMap (64). The
trait under investigation was self-reported; except for subjects
in the Bogalusa Health Study, the subjects included in this
meta-analysis were adults when detailed reproductive history
data were collected. However, recalled age at menarche is
highly correlated with observed age at menarche (65), even 30
years later (66). We did not detect significant heterogeneity
across cohorts in our genetic meta-analysis, but heterogeneity
in data collection methods may have nonetheless contributed
to lower precision of our estimates.
Finally, the timing of menarche is sensitive to early nutritional
status (including body fatness), economic disadvantage and,
more recently, exposure to endocrine-disrupting chemicals
(67), but data on these factors prior to or at the time of menarche
were not available for our study cohorts. Environmental hetero-
geneity between AA and EA women may explain the lack of rep-
lication of some loci, as we did not have adequate data to adjust
for such factors in our analysis. The rate of decline in age at me-
narche over the 20th century was more rapid in AA than EA
women (68), highlighting the potential effects of the changing
nutritional environment for our study population. This is import-
ant because environmental variation between and within popula-
tions may mask genetic effects when those differences are not
accounted for (69,70). Birth year is a potentially useful proxy
for numerous nutritional (e.g. protein intake) and non-nutritional
(e.g. endocrine disruptors) exposures that have changed over
time and may influence developmental timing. It is possible
that one reason for the lack of genome-wide significant findings
in the present analysis is that birth year heterogeneity (and the en-
vironmental variation it may index) could have masked genetic
associations and contributed to our lack of genome-wide signifi-
cant SNP discovery. In this regard, we recently showed a menar-
che genetic risk score-by-birth year interaction effect on
childhood BMI, in which the aggregate effect of 42
menarche-related SNPs was greater in those born recently
when compared with those born earlier in the 20th century in
the same cohort (71). However, in the present study, we had in-
sufficient statistical power to conduct an SNP × birth year inter-
action analysis at the genome-wide level, and it was furthermore
unlikely that this would have significantly altered our
meta-analysis results, as we found little evidence for effect het-
erogeneity across cohorts that varied widely in mean birth year.
Nonetheless, this is a limitation of the present analysis, and an
interesting avenue for future investigation.
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Figure 3. Fine-mapping of the SEC16B locus in AA women reveals a stronger genetic marker for age at menarche than the index SNP identified in European American
women. (A) SNP associations with age at menarche near SEC16B in AAs, using LD from the 1KGP EUR reference panel, in relation to the index SNP rs633715 iden-
tified in EA women (purple diamond). The SNP with the lowest P value in the AA meta-analysis (rs543874) is 0.5 Mb upstream from the index SNP and has signifi-
cantly lower P value (4.9 × 1024 versus 0.12). The two SNPs are in strong LD in EUR populations (red color indicates r2 . 0.8), showing that it would be considered
the same signal in EA women. (B) SNP associations with age at menarche near SEC16B in AAs, using LD from the 1KGP AFR reference panel, in relation to the index
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Conclusions
In summary, we confirmed that many menarche loci identified in
EA women generalize to AA women, and for some of these loci,
examination of AA samples allowed resolution of multiple
signals, better localization of their respective signals and stron-
ger associations with menarche than the originally reported
SNPs. We present findings from the largest genome-wide asso-
ciation meta-analysis of age at menarche in AA women to date
and, although no single SNP reached genome-wide significance,
we identified a number of suggestive associations that may help




A total of 18 089 AA women with self-reported age at menarche
collected at the baseline visit for each study were included in the
Stage 1 meta-analysis. Participants were drawn from seven
population-based cohort studies including the Women’s
Health Initiative (WHI, n ¼ 8086), four cohorts within the Can-
didate Gene Association Resource (CARe): Atherosclerosis
Risk in Communities (ARIC; n ¼ 1690), Coronary Artery
Risk Development in young Adults (CARDIA; n ¼ 630), Cleve-
land Family Study (CFS; n ¼ 169) and Jackson Heart Study
(JHS; n ¼ 1228); the Bogalusa Heart Study (BHS; n ¼ 145),
the Healthy Aging in Neighborhoods of Diversity across the
Life Span study (HANDLS; n ¼ 617) and eight breast cancer
case–control studies in the African American Breast Cancer
Consortium (AABC) (72)(73), including the Carolina Breast
Cancer Study (CBCS; n ¼ 634 cases/586 controls), the Los
Angeles component of the Women’s Contraceptive and Repro-
ductive Experience Study (CARE; n ¼ 357 cases/215 controls),
the Multiethnic Cohort (MEC; n ¼ 532 cases/972 controls), the
Nashville Breast Health Study (NBHS; n ¼ 304 cases/182 con-
trols), the Northern California Breast Cancer Family Registry/
San Francisco Breast Cancer Study (NC-BCFR/SFBCS;
n ¼ 575 cases/269 controls), the Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial (PLCO; n ¼ 56 cases/116 con-
trols), the Wake Forest University Breast Cancer study (WFBC;
n ¼ 112 cases/116 controls), and the Women’s Circle of Health
Study (WCHS; n ¼ 260 cases/238 controls). A further 2850 AA
women in the Black Women’s Health Study (BWHS) were
included in the Stage2. Detailed descriptionsof all studies are pro-
vided in Supplementary Material, Text S1 and Table 1.
Phenotypes
Age at menarche was reported to the whole year, and ranged
from 8 to 21 years of age, except in the case of the MEC, in
which age at menarche was reported within 2-year age groups,
the mid-point of which was used in the analysis. Self-reported
age at menarche in adult women has been shown to be a valid
proxy for prospectively collected age at menarche (66,74,75).
Age at menarche is a normally distributed trait and therefore
was not transformed prior to analysis.
Genotyping and QCs
The Affymetrix Genome-Wide Human SNP array 6.0 (for
ARIC, CARDIA, CFS, JHS, and WHI), the Illumina Human1M-
Duo BeadChip array (for HANDLS, WFBC, WCHS, NBHS,
PLCO, MEC, CBCS, CARE, NC-BCFR, SFBCS) or the Illu-
mina 610K/Illumina CVD SNP array (BHS) is used according
to the manufacturer’s protocol for genome-wide genotyping.
De novo genotyping was conducted at the Broad Institute for
the replication samples using a custom-designed Sequenom
chip and Taqman assays for SNPs that could not be multiplexed.
Several QC filters were applied to the genome-wide genotype
data: DNA concordance checks; sample and SNP genotyping
success rate [.95%, MAF . 1%, minor allele count . 3];
sample heterozygosity rate, identity-by-descent analysis to iden-
tify population outliers, problematic samples and cryptic re-
latedness. A detailed description of the QC checks applied to
the genotypes in each study and consortium is provided in Sup-
plementary Material, Table S1.
SNP imputation
To increase coverage and facilitate comparison with other data-
sets, imputed genotype data were obtained using MACH (76,77),
using all SNPs that passed the QC steps described above, and
employing a 1:1 mixture of HapMap phase II CEU and YRI
data as the reference panel for imputation.
Ancestry estimation
In all cohorts, SNPs on the GWA arrays were subjected to prin-
cipal components analysis using EIGENSTRAT (78) to infer
genetic ancestry. The top 10 principal components were
included in the study-specific genetic association models as cov-
ariates to correct for population stratification.
Association analysis
Within each cohort (and within the breast cancer cases and con-
trols separately in AABC), we tested associations between the
imputed and genotyped SNPs with age at menarche using an
additive genetic model. Linear regression analysis in PLINK
(version 1.07) (79) or ProAbel (80) was used for cohorts of unre-
lated individuals (ARIC, CARDIA, JHS, WHI, BHS, HANDLS
SNP rs633715 identified in EA women (purple diamond). The SNP with the lowest P value in the AA meta-analysis (rs543874) was in relatively weak LD (light blue
color indicates r2 between0.2 and 0.4)with the indexSNP in AFR, suggesting they lie on differenthaplotypes. (C) SNPassociationswith age at menarche near SEC16B
in AAs, using LD from the 1KGP AFR reference panel, in relation to the putatively stronger marker SNP rs543874 (purple diamond). Strong LD in AFR populations
between rs543874 and a cluster of SNPs surrounding it, but low LD with SNPs near the index SNP rs633715 is seen. This suggests rs543874 may better localize the
causal variant giving rise to the association of menarche age with SNPs near SEC16B previously reported in EA women. Note: SNPs are plotted using Locus Zoom by
position on the chromosome against association with age at menarche (2log10 P). Estimated recombination rates are plotted in blue to reflect local LD structure, and
the SNPs surrounding the index SNP (or most significant SNP) in each case are color coded to reflect their LD with this SNP, marked as a purple diamond.
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and all AABC studies) and linear mixed-effect models in R were
used to model family structure for cohorts including related indi-
viduals (CFS). Covariates included the woman’s year of birth (or
age at diagnosis or recruitment for AABC and WHI), if available,
to account for the known secular trends in age at menarche, and
the first ten principal components from EIGENSTRAT to
account for global population stratification.
Meta-analysis
Cohort-specific association results were combined using an
inverse variance-weighted meta-analysis approach as imple-
mented in METAL (81). A genome-wide significance threshold
was set at P ≤ 5 × 1028.
Stage 2 analysis
AA women in the Black Women’s Health Study (BWHS) were
included in the replication stage (description provided in Supple-
mentary Material, Text S1). Given the lack of genome-wide sig-
nificant findings, we used the following serial inclusion criteria
to select top SNPs from the meta-analysis for presentation
(Table 2) and for replication testing: SNPs with P , 1 × 1025
(43 SNPs), SNPs tested in .10 000 women in Stage 1 (yielding
35 SNPs), SNPs with an MAF .0.03 (yielding 34 SNPs) and in-
cluding only SNPs in relatively low LD with other top SNPs
within a 500 kb region (r2 , 0.3) (yielding 20 SNPs). Genotyp-
ing of these 20 SNPs was carried out at the Broad Institute Center
for Genotyping and Analysis using the Sequenom MassArray
iPLEX technology. An average reproducibility of 99.6%
was obtained among the blinded duplicates. The call rate was
98.6% or higher for each SNP. A total of 2850 samples were
included in the final analyses. The top 30 ancestral informative
markers (AIMs) from the Phase 3 admixture panel (82) were gen-
otyped to estimate and control for population stratification due to
European admixture; these 30 AIMs are highly correlated with
estimates from the whole admixture panel and thus provide effi-
cient and valid adjustment for stratification (83). An additive
linear model for associations of age at menarche with genotype
was used, adjusting for year of birth and percent EA as continu-
ous variables. All regression models were run using the SAS stat-
istical software version 9.1.3 (SAS Institute, Inc., Cary, NC,
USA). One SNP could not be accommodated on the panel
(rs4557202) and therefore a proxy SNP in high LD with it
(r2 ¼ 0.967 in 1KG-AFR) was chosen (rs7651087).
Replication of SNP associations in EA women
The 20 SNPs genotyped in the AA replication sample were also
examined for association with age at menarche in the 32-study
Stage 1 meta-analysis results of EA women (26) in over
87 000 women. A Bonferroni-corrected significance threshold
of P , 0.05/20 was applied.
Analysis of secondary signals at known loci
Multiple signals within a single locus in the top GWA results
were evaluated through conditional analyses in the largest
cohort/studies (WHI, CARe and AABC) using individual-level
genotype data. Linear regression analyses were conducted that
included all such SNPs, birth year, study center (if applicable)
and the top 10 PCs as covariates. The results were then
meta-analyzed using METAL and the resulting beta coefficients
and P-values were compared to assess whether there were mul-
tiple independent risk variants within the regions. We applied a
Bonferroni-corrected P-value, correcting for the number of
comparisons to determine the significance of independent
signals.
Interrogation of 42 menarche loci identified in GWAS of EA
women
Our second aim was to interrogate the 42 loci previously reported
to be associated with age at menarche in EA women in our AA
sample (26); 32 of which were genome-wide significant and 10
demonstrated suggestive associations in the previous study.
First, we developed a set of criteria to validate the EA index
SNPs and interrogate regions around each of these 42 loci. For
each index SNP in EA, we looked-up the respective association
result with age at menarche in AA. To accommodate the differ-
ence of LD structure and possible allelic heterogeneity across
different ethnicities, we then interrogated the 250 kb flanking
region around each lead SNP for locus replication to determine
whether there exist other SNPs in the locus with stronger associa-
tions in AA with the outcome. We used the following criteria to
identify the top AA SNP: (i) the SNP with the smallest associ-
ation P-value within the region; (ii) MAF . 0.01; (iii) location
of the AA lead SNP within the same recombination block of
the lead EA SNP, where the recombination block was defined
as a 20% recombination rate. The statistical significance of
each identified SNP was evaluated using a region-specific Bon-
ferroni correction for the multiple comparisons. We determined
the number of independent SNPs based on the variance inflation
factor, which was calculated recursively within a sliding window
with size 50 SNPs and pairwise r2 value of 0.2 using PLINK. If a
SNP was identified with Bonferroni-adjusted P-value ,0.05
within a locus, then this served as evidence of locus replication
in AAs.
Secondly, we interrogated all common genotyped and
imputed SNPs (MAF . 0.01) within the +250 kb flanking
region of the index SNPs to identify, specifically (a) variants
that capture the association in the region in AA women signifi-
cantly better than the index SNP and (b) variants that may repre-
sent secondary signals. We have previously estimated (84) a
threshold of significance for (a) as P , 0.004, which is a correc-
tion based on the number of tag SNPs in the HapMap YRI popu-
lation needed to capture (r2 ≥ 0.8) all SNPs that are correlated
with the index signal in the HapMap CEU (r2 ≥ 0.2). In an
attempt to eliminate minor fluctuations in P-values for correlated
SNPs, we took a more conservative approach than for the condi-
tional analyses and further required the P-value to decrease by
more than one order of magnitude compared with the association
of the EA index signal in AAs. We also required an r2 . 0.4
between the index marker and the more associated marker in
AAs and we assessed phase to ensure that the more associated
marker is on the same haplotype as the GWAS-reported risk
allele in the HapMap CEU population.
For all of the remaining markers that were weakly correlated
(r2 , 0.20) with the index signal (in Europeans), and thus may
define secondary signals, we applied a more stringent a level
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for defining statistical significance. Here we set the threshold as
5.6 × 1026, which is a correction for the number of tag SNPs
needed to capture all common alleles (MAF . 0.05, with r2 .
0.8) in the YRI HapMap population. Both (a) and (b) were esti-
mated empirically based on 30 regions of 500 kb in size in a
previous study of the prostate cancer risk loci (84).
Expression database analysis of menarche SNPs
We queried existing human lymphocyte gene expression data-
bases to determine whether the top SNPs that we identified in
each of the 42 loci (Table 4) were more likely to be associated
with the expression of nearby genes than the originally identified
SNPs in these regions from studies in women of EA. To do so, we
applied a sensitive technique for mapping cis-regulatory SNPs
(85) in 56 unrelated Yoruban African LCLs (YRI LCLs) used
by the HapMap consortium (86).
Statistical power
The Stage 1 meta-analysis of GWA results had ≥80% power to
detect relatively small effect sizes (e.g. 0.12 years, or 6.5 weeks
earlier menarche per copy of the risk allele) for SNPs with
MAF . 0.2 at P , 5 × 1028 (Supplementary Material, Fig. S5).
The Stage 2 replication sample in 2850 women in the BWHS
provided .80% power to detect an SNP having an effect of
7 weeks earlier menarche per copy of the risk allele for alleles
with MAF . 0.25 (which included 13 of the 20 queried variants)
at P , 0.05 corrected for 20 comparisons (Supplementary
Material, Fig. S6).
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